ALK Positive Revenue and Competitors
Estimated Revenue & Valuation
- ALK Positive's total funding is $2M.
Employee Data
- ALK Positive has 14 Employees.
- ALK Positive grew their employee count by 17% last year.
ALK Positive's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP | Reveal Email/Phone |
2 | Philanthropy Manager | Reveal Email/Phone |
3 | ALk Positive Medical Teams | Reveal Email/Phone |
4 | Consultant | Reveal Email/Phone |
ALK Positive Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | N/A | 59 | 34% | N/A | N/A |
#2 | $15M | 37 | 6% | N/A | N/A |
#3 | $3.5M | 10 | N/A | N/A | N/A |
#4 | $3.5M | 32 | 7% | N/A | N/A |
#5 | $300M | 2076 | 43% | N/A | N/A |
#6 | $35M | 65 | -2% | N/A | N/A |
#7 | N/A | 42 | 11% | N/A | N/A |
#8 | $7.5M | 47 | -2% | N/A | N/A |
#9 | N/A | 215 | 38% | N/A | N/A |
#10 | $35M | 72 | 7% | N/A | N/A |
What Is ALK Positive?
ALK Positive is dedicated to improving the life expectancy and quality of life of ALK-positive patients worldwide.
keywords:N/A
$2M
Total Funding
14
Number of Employees
N/A
Revenue (est)
17%
Employee Growth %
N/A
Valuation
N/A
Accelerator
ALK Positive News
2022-04-20 - ALK Translocation in ALK-Positive Mesenchymal Tumors
A wide spectrum of mesenchymal tumors harboring ALK gene rearrangements has been identified outside the archetypal example of ALK-positive...
2022-04-06 - Three Year Follow-Up Data from Phase 3 CROWN Trial of ...
Approximately 25-40% of people with ALK-positive advanced non-small cell lung cancer either have brain metastases at diagnosis or develop...
2022-03-30 - Lung Cancer Research Foundation and ALK Positive ...
(ALK Positive) announce a research partnership to fund ALK-positive related lung cancer projects. Together, they pledge to fund three grants...
Other Companies in Atlanta
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2.1M | 14 | -12% | N/A |
#2 | $1.2M | 14 | N/A | N/A |
#3 | $1.6M | 14 | 27% | N/A |
#4 | $1M | 14 | -7% | N/A |
#5 | $4.9M | 14 | -48% | N/A |